Publications des membres de notre équipe

2026

• Boizard-Moracchini, A. et al. Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis. Nat Commun https://doi.org/10.1038/s41467-026-74452-8 (2026) doi:10.1038/s41467-026-74452-8.
• Pecher, A.-C. et al. Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score. Ann Rheum Dis 85, 1163–1171 (2026).
• Fels, E. et al. Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study. RMD Open 12, e006919 (2026).
• Ruiz-Irastorza, G. et al. Efficacy of the Lupus-Cruces Nephritis protocol in different prognostic groups: a propensity score and cluster analysis. Rheumatology (Oxford) 65, keag214 (2026).
• Betrains, A. et al. Spectrum and significance of 18F-FDG-PET/CT abnormalities in VEXAS syndrome. Rheumatology (Oxford) 65, keag194 (2026).
• Avanoglu-Guler, A. et al. Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database. Rheumatology (Oxford) 65, keag176 (2026).
• Delattre, C. et al. Cervical cancer screening practices among patients with autoimmune and inflammatory rheumatic diseases: a descriptive cross-sectional observational study. BMC Womens Health https://doi.org/10.1186/s12905-026-04475-2 (2026) doi:10.1186/s12905-026-04475-2.
• Tusseau, M. et al. Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus cases. EBioMedicine 126, 106209 (2026).
• Moschetti, L. et al. The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort. Ther Adv Musculoskelet Dis 18, 1759720X261422369 (2026).
• Truchetet, M.-E. et al. Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry. Joint Bone Spine 93, 106021 (2026).
• Cottu, A. et al. Tocilizumab for refractory and/or relapsing polyarteritis nodosa. J Am Acad Dermatol 94, 968–970 (2026).
• Uthurriague, M. et al. Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study. BMC Rheumatol 10, 25 (2026).
• Eviatar, T. et al. Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study. Arthritis Rheumatol 78, 475–482 (2026).
• Campochiaro, C. et al. Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database. Arthritis Rheumatol https://doi.org/10.1002/art.70043 (2026) doi:10.1002/art.70043.
• Campochiaro, C. et al. What have we learned about systemic sclerosis from the EUSTAR database? Curr Opin Rheumatol 38, 53–59 (2026).
• Boulon, C. et al. Nailfold video capillaroscopy predicts severe progression at three years in systemic sclerosis: Results from SCLEROCAP study. Microvasc Res 163, 104874 (2026).

2025

• Subervie, A. et al. Prevalence estimation of a rare disease with the French National Rare Disease Registry: example of TNF receptor associated periodic syndrome (TRAPS). Orphanet J Rare Dis 20, 633 (2025).
• Roth, E. et al. Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort. Rheumatology (Oxford) 64, SI63–SI72 (2025).
• Pauling, J. D. et al. Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosis. Lancet Rheumatol 7, e895–e906 (2025).
• Jeanpierre, M. et al. In silico modeling guides identification of novel JAK1 variants associated with immune dysregulation. EMBO Mol Med 17, 3275–3299 (2025).
• Rivière, E. et al. Cutaneous systemic lupus erythematosus in a woman with skin of colour. CMAJ 197, E1398–E1399 (2025).
• Stammler, R. et al. Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors. Hemasphere 9, e70256 (2025).
• Breillat, P. et al. Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome. Blood 146, 1950–1963 (2025).
• Di Donato, S. et al. Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort. Rheumatology (Oxford) 64, 5354–5363 (2025).
• Velauthapillai, A. et al. Longitudinal association between nailfold capillaroscopy and incident interstitial lung disease: A EUSTAR database analysis. J Scleroderma Relat Disord 10, 368–376 (2025).
• Uthurriague, M. et al. Pharmacology considerations for managing pregnancy in women with systemic lupus erythematosus. Expert Rev Clin Pharmacol 18, 1–17 (2025).
• Trottet, C. et al. Deep hierarchical subtyping of multi-organ systemic sclerosis trajectories – a EUSTAR study. NPJ Digit Med 8, 563 (2025).
• Boucly, A. et al. Pulmonary arterial hypertension in adults with Still’s disease: another pulmonary manifestation associated with HLA-DRB1*15. Ann Rheum Dis 84, 1538–1548 (2025).
• Chiche, L. et al. Entre le normal et le pathologique : le concept de pré-maladie appliqué aux pathologies auto-immunes systémiques. Rev Med Interne 46, 408–414 (2025).
• Arnaud, L. et al. ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Lancet Rheumatol 7, e505–e518 (2025).
• Bjørkekjær, H. J. et al. A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis. Rheumatology (Oxford) 64, 3643–3656 (2025).
• Scherlinger, M. et al. CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol 7, e434–e447 (2025).
• Ruiz-Irastorza, G. et al. Long-term efficacy and safety of the Lupus-Cruces Nephritis protocol: a propensity score study of the Lupus-Cruces and Lupus-Bordeaux cohorts. Lupus Sci Med 12, e001562 (2025).
• Bert-Marcaz, C. et al. Neurological manifestations in patients with VEXAS syndrome. J Neurol 272, 401 (2025).
• Boutinet, S. et al. Anti-CD20 alone as maintenance immunosuppressive therapy in severe lupus nephritis: a promising experience that needs to be evaluated. Lupus Sci Med 12, e001509 (2025).
• Mongin, D. et al. Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database. Arthritis Care Res (Hoboken) 77, 649–657 (2025).
• Yan, Q. et al. Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. Ann Rheum Dis 84, 620–631 (2025).
• Dernoncourt, A. et al. Safety of Fertility Treatments in Women With Systemic Lupus Erythematosus: Data From a Prospective Population-Based Study. BJOG 132, 614–624 (2025).
• Dernoncourt, A. et al. Safety of Fertility Treatments in Women With Systemic Lupus Erythematosus: Data From a Prospective Population-Based Study. BJOG 132, 614–624 (2025).
• Bellando-Randone, S. et al. The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort. Arthritis Res Ther 27, 66 (2025).
• Györfi, A.-H. et al. Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort. J Am Heart Assoc 14, e036730 (2025).
• Du, Y. et al. Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis. J Exp Med 222, e20231809 (2025).
• Alle, G. et al. Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients. Rheumatology (Oxford) 64, 1225–1233 (2025).
• Chaigne, B. et al. Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study. J Autoimmun 152, 103391 (2025).
• Galli, G. et al. Crystalline silica on the lung-environment interface: Impact on immunity, epithelial cells, and therapeutic perspectives for autoimmunity. Autoimmun Rev 24, 103730 (2025).
• Bert-Marcaz, C. et al. Neurological manifestations in patients with VEXAS syndrome. J Neurol 272, 181 (2025).
• de Boysson, H. et al. Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne 46, 4–11 (2025).
• de Boysson, H. et al. French protocol for the diagnosis and management of giant cell arteritis. Rev Med Interne 46, 12–31 (2025).

2024

• Galli, G. et al. Occupational quantitative exposure to crystalline silica, solvents and pesticides and risk of clinical forms of systemic sclerosis. Rheumatology (Oxford) 63, 3397–3406 (2024).
• Didier, K. et al. Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients. RMD Open 10, e004580 (2024).
• Fautrel, B. et al. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Ann Rheum Dis 83, 1614–1627 (2024).
• Khanna, D. et al. Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 63, 3124–3134 (2024).
• Wyss, A. et al. Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis. Arthritis Res Ther 26, 187 (2024).
• Mattuizzi, A. et al. Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology. Nat Commun 15, 9396 (2024).
• Fauthoux, T. et al. Comorbidity burden on mortality in patients with systemic sclerosis. RMD Open 10, e004637 (2024).
• Ruiz-Irastorza, G. et al. No Effect of Low-Dose Glucocorticoid Maintenance Therapy on Damage in SLE Patients in Prolonged Remission: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort. J Clin Med 13, 6049 (2024).
• Colalillo, A. et al. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis. Chest 166, 837–844 (2024).
• Amoura, Z. et al. French protocol for the diagnosis and management of systemic lupus erythematosus. Rev Med Interne 45, 559–599 (2024).
• Ruiz-Irastorza, G. et al. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort. Arthritis Care Res (Hoboken) 76, 1132–1138 (2024).
• Garreau, A. et al. The deficiency of DNASE1L3 does not affect systemic sclerosis pathogenesis in two inducible murine models of the disease. Eur J Immunol 54, e2350903 (2024).
• D’Agostino, J. et al. Concordance and agreement between different activity scores in polymyalgia rheumatica. RMD Open 10, e003741 (2024).
• Archimbaud, J. et al. Demographic and clinical characteristics of patients with coexistence of systemic sclerosis and atopy: A cross-sectional study. J Eur Acad Dermatol Venereol 38, e234–e237 (2024).
• Chehem Daoud Chehem, F. et al. Giant cell arteritis associated with scalp, tongue or lip necrosis: A French multicenter case control study. Semin Arthritis Rheum 64, 152348 (2024).
• De Moreuil, C. et al. History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis. RMD Open 10, e003626 (2024).
• Deibel, E. et al. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time? Arthritis Care Res (Hoboken) 76, 88–97 (2024).
• Gensous, N. et al. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus. Expert Rev Clin Immunol 20, 21–30 (2024).

2023

• Chehem Daoud Chehem F et al.: Giant cell arteritis associated with scalp, tongue or lip necrosis: A French multicenter case control study, Seminars in Arthritis and Rheumatism 64 (2024) 152348
• Frémont de G, Costedoat-Chalumeau N, Lazaro E, Belkhir R, Guettrot-Imbert G, Morel N et al.: Pregnancy outcomes in women with primary Sjögren’s syndrome: an analysis of data from the multicentre, prospective, GR2 study, The Lancet Rheumatology, Vol 5, June 2023, e330-e340,
• Touret, F; Martin-Blondel, G; de Lamballarie, X; Dupont, A; Izopet, J; Mentré, F et al.: Low to undetectable Omicron BQ.1.1 neutralization by patient’s sera a month after initiation of AZD7442 600 mg; Journal of Infection, Février 2023, https://doi.org/10.1016/j.jinf.2023.02.002
• Talarico, R; Ramirez, GA; Barreira, SC; Cardamone, C; Triggianese, P; Aguilera, S et al.: ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products. Clinical and Experimental Rheumatology Mars 2023

2022

• Gottenberg, JE; Chaudier, A; Allenbach, Y; Mekinian, A; Amoura, Z; Cacoub, P : Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases). RMD Open. 2022 Nov;8(2):e002324
• Kuster, S; Jordan S; Elhai, M; Held, U; Steigmiller, K; Bruni, C et al. : Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open 2022 Nov;8(2):e002477
• De La Fuente, F; Belkhir, R; Henry J; Nguyen, CD; Pham, T, Germain, V et al. : Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. RMD Open. 2022 Oct;8(2):e002612. doi: 10.1136/rmdopen-2022-002612.
• Bruni, C ; Heidenreich, S ; Duenas, A ; Hoffmann-Vold, AM ; Gabrielli, A ; Allanore, Y et al. : Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology (Oxford). 2022 Oct 6;61(10):4035-4046. doi: 10.1093/rheumatology/keac126
• Jourde-Chiche, N ; Costedoat-Chalumeau, N ; Baumstarck, K ; Loundou, A ; Bouillet, L ; Burtey, S et al. :  Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis. 2022 Oct;81(10):1420-1427
• Larosa, M ; Le Guern, V ; Guettrot-Imbert, G ; Morel, N ; Abisror, N ; Morati-Hafsaoui, C et al. : Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study. Rheumatology (Oxford). 2022 Aug 30;61(9):3657-3666. doi: 10.1093/rheumatology/keab943
• Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. JAMA. 2022 Sep 20;328(11):1053-1062. doi: 10.1001/jama.2022.15459
• Truchetet ME, Drumez E, Barnetche T, Martin C, Devaux M, Goulenok T, et al.: Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort. RMD Open. 2022 Sep;8(2):e002476. doi: 10.1136/rmdopen-2022-002476. PMID: 36113962.​
• Veccia, A ; Kostine, M ; Tison, A ; Dipasquale, M ; Kinspergher, S ; Prokop, L et al. :  Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis. Joint Bone Spine July 89(4) 2022: 105403 https://doi.org/10.1016/j.jbspin.2022.105403
• Boulon, C ; Velardo, F ; Blaise, S ; Mangin, M ; Chevoir, JD ; Senet, P et al. :  Correlation of nailfold capillaroscopy findings with history of digital ulcer on same finger: Results of SCLEROCAP study. Microvasc Res. 2022 Jul;142:104365. doi: 10.1016/j.mvr.2022.104365
• Iudici, M ; Pagnoux, C ; Courvoisier, DS ; Cohen, P ; Néel, A ; Aouba, A et al. : Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. Rheumatology (Oxford). 2022 May 30;61(6):2464-2471
• Voignier, A ; Skopinski, S ; Duffau, P ; Ribeiro, E ; Biscay, P ; Constans, J et al. :  Descriptive study of pneumococcal vaccination in cases of inflammatory disease: Analysis of practices. Infect Dis Now. 2022 May;52(3):154-159
• Duffau P, Dimicoli S, Gensous N, Truchetet ME, Bordes C. Anti-NOR90 antibody associated with paraneoplastic systemic sclerosis. Clin Exp Rheumatol. 2022 May 4.​
• Bourguiba, R ; Kyheng, M ; Koné-Paut, I ; Rouzaud, D ; Avouac, J ; Devaux, M et al. :  COVID-19 infection among patients with autoinflammatory diseases: a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI – the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases. RMD Open. 2022 May;8(1):e002063. doi: 10.1136/rmdopen-2021-002063
• Galli, G ; Vacher, P ; Ryffel, B ; Blanco, P ; Legembre, P :  Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors. Cells. 2022 Apr 24;11(9):1438. doi: 10.3390/cells11091438
• Jensen, AK ; Chatzidionysiou, K ; Torp, CK ; Sørensen, AS ; Tenstad, HB ; Schäfer, VS et al. : Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy. Joint Bone Spine. 2022 Jul;89(4):105403. doi: 10.1016/j.jbspin.2022.105403
• Cosse, C ; Kernéis, S ; Lescoat, A ; Pugnet, G ; Truchetet, ME ; Priollet, P et al. : Osteitis in Systemic Sclerosis: A Nationwide Case–Control Retrospective Study. Arthritis Care Res (Hoboken). 2022 May;74(5):809-817. doi: 10.1002/acr.24530
• Wacrenier, S ; Riou, J ; Jourdain, P ; Guibert, F ; Henry, N ; Djema, A et al. : Lymphopaenia at diagnosis of anti-neutrophil cytoplasmic antibody-vasculitis with renal involvement is correlated with severity and renal prognosis. Nephrol Dial Transplant. 2022 May 25;37(6):1078-1087.doi: 10.1093/ndt/gfab158.
• Blaise, S ; Boulon, C ; Mangin, M ; Senet, P ; Lazareth, I ; Imbert, B et al. : Finger Systolic Blood Pressure Index Measurement: A Useful Tool for the Evaluation of Arterial Disease in Patients With Systemic Sclerosis. Arthritis Care Res (Hoboken). 2022 May;74(5):828-832. doi: 10.1002/acr.24527
• Hughes, M ; Heal, C ; Henes, J ; Balbir-Gurman, A ; Distler, JHW ; Airò, P et al. : Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology (Oxford). 2022 Mar 2;61(3):1141-1147. doi: 10.1093/rheumatology/keab510
• Thietart, S ; Beinse, G ; Smets, P ; Karras, A ; Philipponnet, C ; Augusto, JF et al. : Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study. J Intern Med. 2022 Mar;291(3):350-363. doi: 10.1111/joim.13417
• Prot-Leurent, C ; Martin-Negrier, ML ; Lazaro, E ; Delbrel, X ; Viallard, JF : Fasciitis secondary to systemic necrotizing vasculitis. QJM. 2022 Mar 22;115(3):164-166. doi: 10.1093/qjmed/hcab308.
• Philippot, Q ; Kannengiesser, C ; Debray, MP ; Gauvain, C ; Ba, I ; Vieri, M et al. : Interstitial lung diseases associated with mutations of poly(A)-specific ribonuclease: A multicentre retrospective study. Respirology. 2022 Mar;27(3):226-235. doi: 10.1111/resp.14195.
• Puéchal, X ; Iudici, M ; Pagnoux, C ; Cohen, P ; Hamidou, M ; Aouba, A et al. :  Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. RMD Open. 2022 Mar;8(1):e002160. doi: 10.1136/rmdopen-2021-002160
• Nezam, D ; Porcher, R ; Grolleau, F ; Morel, P ; Titeca-Beauport, D ; Faguer, S et al. : Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges. J Am Soc Nephrol. 2022 Mar;33(3):628-637. doi: 10.1681/ASN.2021060771
• Papo, M ; Friedrich, C ; Delaval, L ; Boysson, H ; Viallard, JF ; Bachmeyer, C et al. : Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a case–control and exploratory study. Rheumatology (Oxford). 2022 Feb 2;61(2):775-780. doi: 10.1093/rheumatology/keab337
• Riccardi, A ; Martinroche, G ; Contin-Bordes, C ; Avouac, J ; Gobeaux, C ; Cauvet, A et al. Erosive arthritis autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2022 Feb;52:151947. doi: 10.1016/j.semarthrit.2021.11.013.
• Allanore, Y ; Constans, J ; Godard, D ; de Pouvourville, G ; Bouee, S ; Jeanbat, V et al. :  Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. J Scleroderma Relat Disord. 2022 Feb;7(1):49-56. doi: 10.1177/23971983211013979
• Russo, B ; Borowczyk, J ; Cacialli, P ; Moguelet, P ; Truchetet, ME ; Modarressi, A et al. : IL-25 participates in keratinocyte-driven dermal matrix turnover and is reduced in Systemic Sclerosis epidermis. Rheumatology (Oxford). 2022 Feb 16;keac044. doi: 10.1093/rheumatology/keac044
• Delapierre, A ; Terrier, B ; Pillebout, E ; Baudart, P ; Jourde-Chiche, N ; Lioger, B et al.: Clinical phenotype and cytokine profile of adult IgA vasculitis with joint involvement. Clin Rheumatol. 2022 May;41(5):1483-1491.doi: 10.1007/s10067-021-05937-8. Epub 2022 Jan 18.
• Panhaleux, M ; Espitia, O ; Terrier, B ; Manson, G ; Maria, A ; Humbert, S et al. : Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. Eur J Cancer. 2022 Jan;160:134-139. doi: 10.1016/j.ejca.2021.10.018.
• Seror, R ; Camus, M ; Salmon, JH ; Roux, C ; Dernis, E ; Basch, A et al. : Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatol. 2022 Jan;4(1):e8-e11. doi: 10.1016/S2665-9913(21)00314-3

2021

• Laurent P, Lapoirie J, Leleu D, Levionnois E, Grenier C, Jurado-Mestre B, et al. Interleukin-1-β-Activated Microvascular Endothelial Cells Promote DC-SIGN+ Alternative Macrophages Associated with Skin Fibrosis in Systemic Sclerosis. Arthritis Rheumatol 2021 Dec 28. Epub ahead of print. PMID: 34962361.
• Richez C, Cordel N, Maillard H, Willems A, Chasset F, Belot A et al., Practical Management of patients on hydroxychloroquine. Joint Bone Spine 2021 Dez 88 Supl 1 (5): 105316
• Gensous N, Vagner D, Barnetche T, Duffau P, Lazaro E, Richez C, et al., Galectin 9, CXCL-10 and tumor necrosis factor receptor type II as biomarkers of disease activity in systemic lupus erythematosus. Joint Bone Spine 2021 Nov 25;89(3):105311
• Truchetet ME, Brembilla NC, Chizzolini C. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol. 2021 Sep 6, PMID: 34487318
• Lopez L, Griffier R, Barnetche T, Lhomme E, Kostine M, Truchetet M-E, et al. The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis. Rheumatology (Oxford), 2021 Aug 11, keab630
• Hachulla E, Agard C, Allanore Y, Avouac J, Bader-Meunier B, Belot A, et al. French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis 16, 322 (2021)
• Ruiz-Irastorza G, Dueña-Bartolome L, Dunder S, Varona J, Gomez-Carballo C, Dominguez-Cainzos J, et al. Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. Autoimmunity Reviews 20 (2021) 102898 (online ahead of print)
• Scherlinger M, Guillotin V, Douchet I, Vacher P, Boizard-Moracchini A, Guegan J-P, et al. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. Sci. Transl. Med.  30 Jun 2021
• Costedoat I, Masson M, Barnetche T, Duffau P, Lazaro E, Richez C, Seneschal J, et al. Locoregional Treatments for Digital Ulcers in Systemic Sclerosis: A Systematic Review. Acta-Dermato Venereologica May 27 2021 (online ahead of print)
• Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021.
• El-Hout S, Lopez L, Schaeverbeke T, Richez C, Kostine M, Truchetet ME. Rapidly progressive interstitial lung disease under FOLFOX treatment for colorectal cancer associated with systemic sclerosis: two case reports. Rheumatology (Oxford). 2021;60(2):e47-e9.
• Gensous N, Boizard-Moracchini A, Lazaro E, Richez C, Blanco P. Update on the cellular pathogenesis of lupus. Curr Opin Rheumatol. 2021;33(2):190-6.
• Lazzaroni MG, Marasco E, Campochiaro C, DeVries-Bouwstra J, Gonzalez-Perez MI, Rojas-Serrano J, et al. The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology (Oxford). 2021.
• Russo B, Borowczyk J, Boehncke WH, Truchetet ME, Modarressi A, Brembilla NC, et al. Dysfunctional keratinocytes increase dermal inflammation in systemic sclerosis. Results from tissue-engineered scleroderma epidermis. Arthritis Rheumatol. 2021.
• Scherlinger M, Lutz J, Galli G, Richez C, Gottenberg JE, Sibilia J, et al. Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments. Semin Arthritis Rheum. 2021;51(1):36-42.
• Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021.
• Vial G, Gensous N, Savel H, Richez C, Lazaro E, Truchetet ME, et al. The impact of clopidogrel on plasma-soluble CD40 ligand levels in systemic lupus erythematosus patients: the CLOPUS phase I/II pilot study. Joint Bone Spine. 2021;88(2):105097.

2020

• Brilland B, Scherlinger M, Khoryati L, Goret J, Duffau P, Lazaro E, et al. Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus. Clin Rev Allergy Immunol. 2020;58(2):194-212.
• Cosse C, Kerneis S, Lescoat A, Pugnet G, Truchetet ME, Priollet P, et al. Osteitis in Systemic Sclerosis: a nationwide case-control retrospective study (SCLEROS Study). Arthritis Care Res (Hoboken). 2020.
• Dufour AM, Borowczyk-Michalowska J, Alvarez M, Truchetet ME, Modarressi A, Brembilla NC, et al. IL-17A Dissociates Inflammation from Fibrogenesis in Systemic Sclerosis. J Invest Dermatol. 2020;140(1):103-12 e8.
• Felten R, Devauchelle-Pensec V, Seror R, Duffau P, Saadoun D, Hachulla E, et al. Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2020.
• Gossec L, Molto A, Beauvais C, Senbel E, Flipo RM, Pouplin S, et al. Agreement with the French 2019 recommendations on treatment adherence in rheumatic diseases among 357 health professionals. Joint Bone Spine. 2020;87(5):513-5.
• Grange L, Guilpain P, Truchetet ME, Cracowski JL, French Society of P, Therapeutics. Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. Therapie. 2020;75(4):335-42.
• Hassler S, Bachelet D, Duhaze J, Szely N, Gleizes A, Hacein-Bey Abina S, et al. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Med. 2020;17(10):e1003348.
• Henrot P, Laurent P, Levionnois E, Leleu D, Pain C, Truchetet ME, et al. A Method for Isolating and Culturing Skin Cells: Application to Endothelial Cells, Fibroblasts, Keratinocytes, and Melanocytes From Punch Biopsies in Systemic Sclerosis Skin. Front Immunol. 2020;11:566607.
• Henrot P, Moisan F, Laurent P, Manicki P, Kaulanjan-Checkmodine P, Jolivel V, et al. Decreased CCN3 in Systemic Sclerosis Endothelial Cells Contributes to Impaired Angiogenesis. J Invest Dermatol. 2020;140(7):1427-34 e5.
• Henrot P, Moisan F, Seneschal J, Taieb A, Cario M, Truchetet ME. Is Hyperpigmentation in Systemic Sclerosis a Perivascular Dermal Tattoo? J Invest Dermatol. 2020;140(11):2308-12 e2.
• Henrot P, Pain C, Taieb A, Truchetet ME, Cario M. Dysregulation of CCN3 (NOV) expression in the epidermis of systemic sclerosis patients with pigmentary changes. Pigment Cell Melanoma Res. 2020;33(6):895-8.
• Hillion S, Arleevskaya MI, Blanco P, Bordron A, Brooks WH, Cesbron JY, et al. The Innate Part of the Adaptive Immune System. Clin Rev Allergy Immunol. 2020;58(2):151-4.
• Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, et al. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis. 2020;79(5):618-25.
• Ledoult E, Launay D, Behal H, Mouthon L, Pugnet G, Lega JC, et al. Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. Arthritis Res Ther. 2020;22(1):30.
• Leleu D, Levionnois E, Laurent P, Lazaro E, Richez C, Duffau P, et al. Elevated Circulatory Levels of Microparticles Are Associated to Lung Fibrosis and Vasculopathy During Systemic Sclerosis. Front Immunol. 2020;11:532177.
• Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020;382(3):211-21.
• Najm A, Kostine M, Pauling JD, Ferreira AC, Stevens K, Smith E, et al. Multidisciplinary collaboration among young specialists: results of an international survey by the emerging EULAR network and other young organisations. RMD Open. 2020;6(2).
• Noel N, Le Roy A, Hot A, Saadoun D, Lazaro E, Levesque H, et al. Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. Autoimmun Rev. 2020;19(3):102464.
• Richez C, Flipo RM, Berenbaum F, Cantagrel A, Claudepierre P, Debiais F, et al. Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. Joint Bone Spine. 2020;87(5):431-7.
• Richez C, Lazaro E, Lemoine M, Truchetet ME, Schaeverbeke T. Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. Joint Bone Spine. 2020;87(3):187-9.
• Ruyssen-Witrand A, Soubrier M, Basch A, Truchetet ME, Seror R. Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’. Ann Rheum Dis. 2020.
• Scherlinger M, Mertz P, Sagez F, Meyer A, Felten R, Chatelus E, et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev. 2020;19(6):102531.

2019

• Boulon C, Aiouaz S, Blaise S, Mangin M, Decamps-Le Chevoir J, Senet P, et al. Correlation between capillaroscopic classifications and severity in systemic sclerosis: results from SCLEROCAP study at inclusion. Clin Exp Rheumatol. 2019;37 Suppl 119(4):63-8.
• Chasset F, Richez C, Martin T, Belot A, Korganow AS, Arnaud L. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). Joint Bone Spine. 2019;86(2):165-71.
• Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78(7):979-87.
• Galli G, Poissonnier A, Guegan JP, Charrier M, Sisirak V, Lazaro E, et al. HIV protease inhibitors and autoimmunity: An odd, but promising idea. Autoimmun Rev. 2019;18(10):102370.
• Gossec L, Molto A, Romand X, Puyraimond-Zemmour D, Lavielle M, Beauvais C, et al. Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. Joint Bone Spine. 2019;86(1):13-9.
• Henrot P, Truchetet ME, Fisher G, Taieb A, Cario M. CCN proteins as potential actionable targets in scleroderma. Exp Dermatol. 2019;28(1):11-8.
• Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO, 3rd, Richez C, et al. Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis. 2019;78(6):860-2.
• Kostine M, Richez C, Schaeverbeke T, Fhu A. Response to: ‘Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1’ by Michot et al and ‘Checkpoint inhibitor-associated immune arthritis’ by Arnaud et al. Ann Rheum Dis. 2019;78(7):e69.
• Kostine M, Truchetet ME, Schaeverbeke T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology (Oxford). 2019;58(Suppl 7):vii68-vii74.
• Lande R, Lee EY, Palazzo R, Marinari B, Pietraforte I, Santos GS, et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-alpha production in systemic sclerosis. Nat Commun. 2019;10(1):1731.
• Leroy V, Henrot P, Barnetche T, Cario M, Darrigade AS, Manicki P, et al. Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: Analysis of a cohort of 239 patients. J Am Acad Dermatol. 2019;80(2):478-84.
• Meunier P, Dequidt L, Barnetche T, Lazaro E, Duffau P, Richez C, et al. Increased risk of mortality in systemic sclerosis-associated digital ulcers: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(2):405-9.
• Najm A, Nikiphorou E, Kostine M, Richez C, Pauling JD, Finckh A, et al. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open. 2019;5(2):e001014.
• Richez C, Morel J, Cornec D, Daien C, Goupille P, Lazaro E, et al. Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). Joint Bone Spine. 2019;86 Suppl 1:eS2-eS103.
• Riviere E, Schwartz P, Machelart I, Greib C, Pellegrin JL, Viallard JF, et al. Neurosarcoidosis and infliximab therapy monitored by 18FDG PET/CT. QJM. 2019;112(9):695-7.
• Ruiz-Irastorza G, Ruiz-Estevez B, Lazaro E, Ruiz-Arruza I, Duffau P, Martin-Cascon M, et al. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmun Rev. 2019;18(9):102359.
• Scherlinger M, Carcaud C, Truchetet ME, Barnetche T, Duffau P, Couzi L, et al. Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study. Ann Rheum Dis. 2019;78(7):1007-10.

2018

• Augusto JF, Truchetet ME, Charles N, Blanco P, Richez C. IgE in lupus pathogenesis: Friends or foes? Autoimmun Rev. 2018;17(4):361-5.
• Belizna C, Pregnolato F, Abad S, Alijotas-Reig J, Amital H, Amoura Z, et al. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev. 2018;17(12):1153-68.
• Eyraud A, Scouppe L, Barnetche T, Forcade E, Lazaro E, Duffau P, et al. Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature. Br J Dermatol. 2018;178(3):650-8.
• Gensous N, Charrier M, Duluc D, Contin-Bordes C, Truchetet ME, Lazaro E, et al. T Follicular Helper Cells in Autoimmune Disorders. Front Immunol. 2018;9:1637.
• Guillotin V, Bouhet A, Barnetche T, Richez C, Truchetet ME, Seneschal J, et al. Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis. Joint Bone Spine. 2018;85(6):663-8.
• Henrot P, Foret J, Barnetche T, Lazaro E, Duffau P, Seneschal J, et al. Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis. Joint Bone Spine. 2018;85(2):155-63.
• Jacquemin C, Augusto JF, Scherlinger M, Gensous N, Forcade E, Douchet I, et al. OX40L/OX40 axis impairs follicular and natural Treg function in human SLE. JCI Insight. 2018;3(24).
• John G, Avouac J, Piantoni S, Polito P, Fredi M, Cozzi F, et al. Prevalence and Disease-Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. Arthritis Care Res (Hoboken). 2018;70(8):1218-27.
• Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393-8.
• Laurent P, Sisirak V, Lazaro E, Richez C, Duffau P, Blanco P, et al. Innate Immunity in Systemic Sclerosis Fibrosis: Recent Advances. Front Immunol. 2018;9:1702.
• Poissonnier A, Guegan JP, Nguyen HT, Best D, Levoin N, Kozlov G, et al. Disrupting the CD95-PLCgamma1 interaction prevents Th17-driven inflammation. Nat Chem Biol. 2018;14(12):1079-89.
• Salliot C, Denis A, Dernis E, Andre V, Perdriger A, Albert JD, et al. Ultrasonography and detection of subclinical joints and tendons involvements in Systemic Lupus erythematosus (SLE) patients: A cross-sectional multicenter study. Joint Bone Spine. 2018;85(6):741-5.
• Scherlinger M, Guillotin V, Truchetet ME, Contin-Bordes C, Sisirak V, Duffau P, et al. Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. Autoimmun Rev. 2018;17(6):625-35.
• Smirani R, Truchetet ME, Poursac N, Naveau A, Schaeverbeke T, Devillard R. Impact of systemic sclerosis oral manifestations on patients’ health-related quality of life: A systematic review. J Oral Pathol Med. 2018;47(9):808-15.
• Truchetet ME, Pradeu T. Re-thinking our understanding of immunity: Robustness in the tissue reconstruction system. Semin Immunol. 2018;36:45-55.

2017

• Alunno A, Studenic P, Nikiphorou E, Balazova P, van Nieuwkoop L, Ramiro S, et al. Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists’ and EULAR Young PARE perspectives. RMD Open. 2017;3(2):e000514.
• Boulon C, Devos S, Mangin M, Decamps-Le Chevoir J, Senet P, Lazareth I, et al. Reproducibility of capillaroscopic classifications of systemic sclerosis: results from the SCLEROCAP study. Rheumatology (Oxford). 2017;56(10):1713-20.
• Gensous N, Doassans-Comby L, Lazaro E, Duffau P. Systemic lupus erythematosus and contraception: A systematic literature review [article in French]. Rev Med Interne. 2017;38(6):358-67.
• Gensous N, Marti A, Barnetche T, Blanco P, Lazaro E, Seneschal J, et al. Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review. Arthritis Res Ther. 2017;19(1):238.
• Gensous N, Schmitt N, Richez C, Ueno H, Blanco P. T follicular helper cells, interleukin-21 and systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(4):516-23.
• Henrot P, Truchetet ME, Cario-Andre M. Are Murine Fibroblasts Responsible for Fibrosis Reversion? Comment on the Article by Luchetti et al. Arthritis Rheumatol. 2017;69(8):1703.
• Jacquemin C, Rambert J, Guillet S, Thiolat D, Boukhedouni N, Doutre MS, et al. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. Br J Dermatol. 2017;177(5):1367-75.
• John G, Allanore Y, Polito P, Piantoni S, Fredi M, Avouac J, et al. The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. Rheumatology (Oxford). 2017;56(11):1874-83.
• Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16(6):650-7.
• Kostine M, Chiche L, Lazaro E, Halfon P, Charpin C, Arniaud D, et al. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. Rev Med Interne. 2017;38(8):513-25.
• Laurent P, Jolivel V, Manicki P, Chiu L, Contin-Bordes C, Truchetet ME, et al. Immune-Mediated Repair: A Matter of Plasticity. Front Immunol. 2017;8:454.
• Lazaro E, Scherlinger M, Truchetet ME, Chiche L, Schaeverbeke T, Blanco P, et al. Biotherapies in systemic lupus erythematosus: New targets. Joint Bone Spine. 2017;84(3):267-74.
• Le Gallo M, Poissonnier A, Blanco P, Legembre P. CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases. Front Immunol. 2017;8:1216.
• Monlun M, Hyernard C, Blanco P, Lartigue L, Faustin B. Mitochondria as Molecular Platforms Integrating Multiple Innate Immune Signalings. J Mol Biol. 2017;429(1):1-13.
• Riviere E, Cohen Aubart F, Maisonobe T, Maurier F, Richez C, Gombert B, et al. Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. J Neurol. 2017;264(6):1218-26.
• Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, Lazaro E, Iza A, Couzi L, et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826-32.
• Scherlinger M, Schaeverbeke T, Blanco P, Richez C. A unilateral erosive arthritis in a patient with systemic lupus erythematosus. Joint Bone Spine. 2017;84(2):245-6.
• Scherlinger M, Sisirak V, Richez C, Lazaro E, Duffau P, Blanco P. New Insights on Platelets and Platelet-Derived Microparticles in Systemic Lupus Erythematosus. Curr Rheumatol Rep. 2017;19(8):48.

2016

• Blanco P, Ueno H, Schmitt N. T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis. Eur J Immunol. 2016;46(2):281-90.
• Contis A, Vanquaethem H, Truchetet ME, Couzi L, Rigothier C, Richez C, et al. Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. Clin Rheumatol. 2016;35(2):517-22.
• Cunin P, Beauvillain C, Miot C, Augusto JF, Preisser L, Blanchard S, et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. Cell Death Dis. 2016;7:e2215.
• Darrigade AS, Vedie AL, Gauthier C, Cario-Andre M, Taieb A, Truchetet ME, et al. Pigmented skin patches without scleroderma as a predominant clinical symptom revealing systemic sclerosis. Clin Exp Dermatol. 2016;41(4):379-82.
• Ducreux J, Houssiau FA, Vandepapeliere P, Jorgensen C, Lazaro E, Spertini F, et al. Interferon alpha kinoid induces neutralizing anti-interferon alpha antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon alpha kinoid phase I/II study. Rheumatology (Oxford). 2016;55(10):1901-5.
• Duron L, Cohen-Aubart F, Diot E, Borie R, Abad S, Richez C, et al. Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev. 2016;15(10):994-1000.
• Gossec L, Baillet A, Dadoun S, Daien C, Berenbaum F, Dernis E, et al. Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. Joint Bone Spine. 2016;83(5):501-9.
• Khoryati L, Augusto JF, Shipley E, Contin-Bordes C, Douchet I, Mitrovic S, et al. IgE Inhibits Toll-like Receptor 7- and Toll-like Receptor 9-Mediated Expression of Interferon-alpha by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016;68(9):2221-31.
• Poissonnier A, Sanseau D, Le Gallo M, Malleter M, Levoin N, Viel R, et al. CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. Immunity. 2016;45(1):209-23.
• Puges M, Biscay P, Barnetche T, Truchetet ME, Richez C, Seneschal J, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2016;55(9):1664-72.
• Truchetet ME, Demoures B, Eduardo Guimaraes J, Bertrand A, Laurent P, Jolivel V, et al. Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis. Arthritis Rheumatol. 2016;68(11):2784-94.
• Turpin D, Truchetet ME, Faustin B, Augusto JF, Contin-Bordes C, Brisson A, et al. Role of extracellular vesicles in autoimmune diseases. Autoimmun Rev. 2016;15(2):174-83.